SecBot SecBot
Insider Cluster (2 insiders) ·Filed Jul 7, 2026

IMNM

Immunome Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed4mo ago
Insider cluster: 2 insiders, $2.2M total
Actionable Insight • Neutral

The insider selling is too small to warrant a bearish read. Routine derivative exercises and sales by a CMO and director are common for liquidity and tax planning. Monitor for any upcoming clinical catalysts or earnings news that could provide context, but no immediate action is required.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$24.01
T+0 close · Jul 7, 2026 · via day close
Latest settled
−12.99%
T+60 · $20.89
Vs SPY
−15.49%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 8 $24.01entry
  2. T+1 · 4mo ago +0.67%α −0.18% · $24.17
  3. T+5 · 4mo ago −5.91%α −6.78% · $22.59
  4. T+20 · 3mo ago +6.29%α +3.02% · $25.52
  5. T+60 · 7w ago −12.99%α −15.49% · $20.89
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Two insiders at Immunome (CMO and a director) sold shares totaling $2.19M in open-market transactions over a 7-day window. The sales represent less than 0.1% of the company's $2.7B market cap, making them routine and non-material. No specific catalyst or pattern suggests informed selling.

Key Financial Metrics

Direction
selling
Total Value
$2.2M
Insiders
2

Key Facts

  • Total open-market sales of $2.19M by two insiders (CMO Robert Lechleider and Director Isaac Barchas) over a 7-day window ending July 2, 2026.
  • Sales represent approximately 0.08% of Immunome's $2.7B market cap, well below the 0.1% materiality threshold.
  • CMO Lechleider also exercised 110,000 stock options (55,000 at $0 and 55,000 at $8.73) concurrently with the sales, a common pattern to cover tax obligations or generate liquidity.

Financial Impact

Negligible, less than 0.1% of market cap sold.

dilution

Risk Factors

  • Insider selling could continue if the stock price appreciates further, but the current level is immaterial.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-IMNM-1783461710403

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 7, 2026